Amgen's MariTide Diabetes Study Expected to Read Out in Q4 2025

Amgen expects a Q4 2025 readout from its Phase 2 study investigating MariTide for Type 2 diabetes treatment in adults with and without obesity. The company previously guided the readout for the second half of 2025. Amgen's shares are down 5% to $285.70 in morning trading following its Q2 report.

Amgen Inc (AMGN) reported a 9% year-over-year (YoY) revenue increase in Q2 2025, driven by a 13% increase in volume. The company's diverse portfolio saw significant sales growth across key products, with fifteen products delivering double-digit sales growth [1]. The non-GAAP tax rate decreased to 14.2%, a 0.7 percentage point decrease from the previous year [1].

Amgen's biosimilars portfolio grew by 40% YoY, contributing significantly to top-line growth and generating meaningful cash flows [1]. The company is leveraging AI to enhance innovation and productivity across its operations, from discovery to commercial execution [1].

Despite the positive results, Amgen faces challenges such as declining net selling prices for medicines across the industry, which could impact future revenue growth [1]. Prolia sales declined 4% YoY due to lower net selling prices and competition from biosimilars [1]. The company also anticipates fluctuations in sales for certain products like WEZLANA and AMGEVITA, which could lead to revenue volatility [1].

Amgen's shares are down 5% to $285.70 in morning trading following its Q2 report. The company expects a Q4 2025 readout from its Phase 2 study investigating MariTide for Type 2 diabetes treatment in adults with and without obesity. The company previously guided the readout for the second half of 2025 [1].

References:
[1] https://www.gurufocus.com/news/3038937/amgen-inc-amgn-q2-2025-earnings-call-highlights-strong-revenue-growth-and-robust-pipeline-drive-optimism